$4.97
+0.00 (+0.00%)
Last updated: Jul 15, 2026 04:33
Fundamentals Overview
bluebird bio, Inc. is in the middle of its 52-week range with low valuation, trading relatively flat today.
Valuation low
Risk (Beta)
0.37 — lower vol
BullzEye Analysis
Our composite tilts Hold on technicals (e.g. RSI, ADX, trend), fundamentals, sentiment, sector and index context, and risk.
Composite Signal
Supporting (Buy):
Sentiment improving (4 upgrades)
Not financial advice. For education and research only; do your own research and consider a financial advisor before investing.
Key Stats
About
Ratings & Grades at a Glance
Recent institutional grades: majority upgrades. Current institutional positions: Buy: 4, Equal Weight: 5, Market Perform: 1, Neutral: 5, Outperform: 3, Overweight: 5, Reduce: 1, Sector Perform: 3, Underweight: 3.
Valuation & Ratios
Valuation, liquidity, and profitability metrics are consolidated here (including ratios that previously appeared in the Financials story). Trailing (TTM) vs forward-looking (e.g. DCF) is noted on each line where it matters.
DCF vs price: DCF estimate is $-406.92; current price is $4.97. That’s a -8287.5% gap. When the gap is large (e.g. >20%), that’s divergence; when they’re close, that’s convergence. Differences can reflect growth expectations, sector premiums, or conservative vs. optimistic assumptions. Use DCF as one input alongside technicals and sentiment.
| Metric | Value |
|---|---|
| Valuation | |
| P/E (TTM) | N/A |
| PEG (TTM) | N/A |
| P/B (TTM) | N/A |
| P/S (TTM) | 0.58 |
| Liquidity & enterprise | |
| Current Ratio (TTM) | 0.48 |
| Quick Ratio (TTM) | 0.28 |
| Cash Ratio (TTM) | 0.19 |
| Profitability | |
| ROE (TTM) | N/A |
| ROA (TTM) | N/A |
| Revenue growth (YoY) | N/A |
| Net margin (TTM) | -2.87% |
| Gross margin (TTM) | -6.65% |
| Operating margin (TTM) | -3.23% |
| Debt to equity (TTM) | N/A |
Latest News
News loads when you open this tab.
Price Target, Ratings & Grades
Analyst price targets, consensus, rating snapshot, and institutional grades for BLUE.
Analyst Sentiment at a Glance
Stock Grades (Institutions)
| Institution | Action | Previous Grade | New Grade | Date |
|---|---|---|---|---|
| Barclays | maintain | Overweight | Overweight | 2025-03-31 |
| Wells Fargo | maintain | Equal Weight | Equal Weight | 2025-02-24 |
| JP Morgan | upgrade | Underweight | Neutral | 2025-02-24 |
| Barclays | maintain | Overweight | Overweight | 2024-12-31 |
| B of A Securities | downgrade | Buy | Neutral | 2024-11-15 |
| RBC Capital | maintain | Sector Perform | Sector Perform | 2024-11-15 |
| Barclays | maintain | Overweight | Overweight | 2024-11-15 |
| Wells Fargo | maintain | Equal Weight | Equal Weight | 2024-09-25 |
| JP Morgan | downgrade | Overweight | Neutral | 2024-08-15 |
| Barclays | maintain | Overweight | Overweight | 2024-08-15 |
| RBC Capital | maintain | Sector Perform | Sector Perform | 2024-08-15 |
| B of A Securities | maintain | Buy | Buy | 2024-08-15 |
| Baird | maintain | Outperform | Outperform | 2024-08-15 |
| RBC Capital | maintain | Sector Perform | Sector Perform | 2024-03-27 |
| Wells Fargo | maintain | Equal Weight | Equal Weight | 2024-03-27 |
| Wedbush | maintain | Neutral | Neutral | 2024-03-19 |
| HSBC | maintain | Reduce | Reduce | 2024-03-05 |
| B of A Securities | maintain | Buy | Buy | 2023-12-21 |
| Wells Fargo | maintain | Equal Weight | Equal Weight | 2023-12-15 |
| Baird | maintain | Outperform | Outperform | 2023-12-12 |
| B of A Securities | maintain | Buy | Buy | 2023-12-11 |
| Morgan Stanley | upgrade | Underweight | Equal Weight | 2023-12-08 |
| Raymond James | maintain | Outperform | Outperform | 2023-11-08 |
| B of A Securities | upgrade | Neutral | Buy | 2023-07-19 |
| Morgan Stanley | maintain | Underweight | Underweight | 2023-07-11 |
| Barclays | upgrade | Equal Weight | Overweight | 2023-06-01 |
| Morgan Stanley | maintain | Underweight | Underweight | 2023-04-03 |
| B of A Securities | maintain | Neutral | Neutral | 2023-03-30 |
| Morgan Stanley | maintain | Underweight | Underweight | 2023-01-24 |
| SVB Leerink | maintain | Market Perform | Market Perform | 2023-01-23 |